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Abstract
Objective: The aim of this study was to investigate the feasibility of transventricular—transseptal approach (TVSA) for extrapleural trans-
catheter aortic valved stent implantation via a subxyphoidian access. Methods: In five porcine experiments (52.3  10.9 kg) the right ventricle
was exposed via subxyphoidian access. Under the guidance of intracardiac echocardiography (ICE) and fluoroscopy, the transseptal access from
right ventricle to left ventricle was created progressively by puncture and dilation with dilators (8F—26F). Valved stents built in-house from
commercial tanned pericardium and self-expandable Nitinol stents were loaded into a cartridge. A delivery sheath was then introduced from the
right ventricle into the left ventricle and then into the ascending aorta. The cartridge was connected and the valved stent was deployed in the
aortic position. Then, the ventricular septal access was sealed with an Amplatzer septal occluder device and the right ventricular access was
closed by tying prepared purse-string suture directly. Thirty minutes after the whole procedure, the animals were sacrificed for macroscopic
evaluation of the position of valved stent and septal closure device. Result: Procedural success of TVSA was 100% at the first attempt. Mean
procedure time was 49  4 min. Progressive dilatation of the transseptal access resulted in a measurable ventricular septal defect (VSD) after
dilator sizes 18F and more. All valved stents were delivered at the target site over the native aortic valve with good acute valve function and no
paravalvular leaks. During the procedure, premature beats (5/5) and supraventriclar tachycardias (5/5) were observed, but no atrial-ventricular
block (0/5) occurred. Heart rate before (after) was 90  3 beats min1 (100  2 beats min1: p < 0.05), whereas blood pressure was
60  1 mm Hg (55  2 mm Hg ( p < 0.05)). Total blood loss was 280  10 ml. The Amplatzer septal occluder devices were fully deployed and
the ventricular septal accesses were sealed successfully, without detectable residual shunt. Conclusion: Trans-catheter implantation of aortic
valved stent via extrapleural transventricular—transseptal access is technically feasible and has the potential for a simplified procedure under
local anaesthesia.
# 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Trans-catheter aortic valve implantation (TAVI) [1] is
growing rapidly and it has been demonstrated for the trans-
apical route [2,3] that an excellent result can be achieved
with minimal risk of stroke or atrial-ventricular block [4,5],
and, of course no damage of access vessels. However, the
trans-apical route has so far been realised through a mini-
thoracotomy, which, in turn, requires general anaesthesia.
We have previously reported a video-endoscopic approach
[6], which has been realised in the experimental setting in
combination with modified closure devices [7,8] to achieve§ Dr Ligang Liu benefits from the post-thoracic residency fellowship for a 1-
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doi:10.1016/j.ejcts.2010.04.033rapid sealing of the trans-apical access orifice. Although this
approach is less invasive, it is still a transpleural route with
all its limitations.
The opening of the pleural space can be avoided with a
subxyphoid access, and we have used this route for
implantation of a stent valve into a right ventricle (RV)-
pulmonary artery conduit with a degenerated valve by
puncture of the right ventricle [9]. In the experimental
setting, we have also reached the left ventricle and the aorta
from a subxyphoid or rather a trans-umbilical approach to
implant an aortic stent-valve through a natural orifice [10]
for namely, Natural Orifice Translumenal Endoscopic Surgery
[11]. Interestingly enough, the pulmonary artery and the
aorta could be accessed both in reproducible fashion with this
experimental single port approach in combination with
closure devices for sealing of the transparietal ventricular
access orifices.
In the clinical setting, however, it appears to be more
difficult to access the left ventricle with a subxyphoid
technique because of the natural position of the humanSurgery. Published by Elsevier B.V. All rights reserved.
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antero-diaphragmatic position, whereas the left ventricle is
usually latero-posterior. Hence, the idea was to approach the
aortic root in transventricular—transseptal fashion by passing
through the right ventricle and the septum to reach the left
side and ultimately the aortic route.2. Materials and methods
2.1. Valved stent construction
The valved stents used in this study were built from two
components: a double-crowned [12] self-expandable Nitinol
stent [13] with a waist diameter of 25 mm (Symetis SA,
Lausanne, Switzerland, shown in Fig. 1(D)) and inside a
pericardial valve, which was made in-house from glutar-
aldehyde-preserved equine pericardium as shown in
Fig. 1(A)—(C)). In vitro bench tests were realised with the
Dynatek Dalta MP3 system as previously reported [13].
2.2. Delivery system
The stent-valve delivery system was based on a commer-
cial introducer for trans-apical aortic valve implantations
with an external diameter of 30F and total length of 22 cm,
which was modified for use with a self-expanding stent-valve
design by adding a pusher with a blunt tip. The valved stent
was compressed with a commercial crimper over a guide wire
and a catheter, and loaded into a cartridge. Once the
introducer was positioned in transventricular—transseptal
fashion, the cartridge was connected to the valved sheath
and the stent valve was transferred with the pusher. No
balloon was necessary to deliver the thermosensitive Nitinol
stent, which expanded immediately as soon as it was released
from the sheath.
2.3. Access closure device
An Amplatzer muscular septal occluder (AGA Medical
Corp, Golden Valley, MN, USA), which is made of wovenFig. 1. The self-expandable valved Nitinol stent, which consisted of a self-
expandable Nitinol stent (D) and a homemade equine pericardial trileaflet
valve with single point attachment (A, B and C).Nitinol wires into two self-expandable round concave
retention disks with a connecting 7-mm waist, was used to
seal the transventricular septal access after the deployment
of the aortic valved stent. To pass more easily through the
ventricular septal access, the Amplatzer delivery system was
modified to allow for a monorail technique. After implanta-
tion of the aortic valved stent, the same guide wire was used
to insert the closure device for sealing off the transseptal left
ventricular access.
All of the above devices underwent thorough in vitro
testing prior to the experimental in vivo implantation. All
animals received care in compliance with ‘the Principles
of Laboratory Animals’ formulated by the National Society of
Medical Research and ‘the Guide for the Care and Use of
Laboratory Animals’ prepared by the Institute of Laboratory
Animal Resources and published by the National Institute of
Health (NIH publication 85-23, revised 1985). The protocol
was approved by the State Committee on Animal Research.
2.4. Surgical access
An acute in vivo evaluation was performed in five porcine
experiments, aged from 9 to 12 weeks, with a mean body
weight of 52.3  10.9 kg. Before the procedure, general
anaesthesia was induced with 22 mg kg1 ketamine,
0.8 mg kg1 atropine administered intramuscularly, and
15 mg kg1 thiopental administered through a superficial vein
of the right ear. Under general anaesthesia maintained with
volatile anaesthetics, and mechanical ventilation, bilateral
internal jugular veins and arteries were exposed. An
intravenous line was placed in the right jugular vein. Then,
the arterial pressure line was inserted into the right carotid
artery. The left jugular vein was mobilised for the insertion of
an intracardiac echocardiographic probe (ICE: Accuson
Navigate, Accuson, Siemens, Munich, Germany). Continuous
monitoring of electrocardiography, arterial pressure, central
venous pressure and oxygen saturation was routine. The
subxyphoid to paraxyphoid area was prepared and a 5-cm
incision was made. Then, the diaphragmatic face of the right
ventricle was exposed. A double 2/0 purse-string monofila-
ment suture reinforced with felt pledgets was prepared in a
zone of myocardium, without coronary arteries, on the
diaphragmatic side of the right ventricle.
2.5. Transventricular-transseptal aortic valved stent
implantation
First, the left ventricular outflow tract dimensions and the
native aortic valve, including annular diameter, valvular
surface andmorphology of the aortic root were visualised and
measured by intracardiac ultrasound. Then, a valved stent of
optimal size was crimped and loaded into the delivery
cartridge as outlined above. After systemic heparinisation
(LiquemineW, Roche, Switzerland: 100 IU kg1), the prepared
area of right ventricle was punctured with a needle, followed
by a guide wire, and then an over-the-wire 8F introducer
system (Arrows, Reading, PA, USA) was inserted crossing the
right ventricular cavity and the ventricular septum into the
left ventricle. Under ICE and fluoroscopic guidance, a soft-tip
J-type STARTER guide wire (0.035 inches, 180 cm; Boston
Scientific, Natick, MA, USA) was first introduced into the left
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Fig. 2. The set of dilators used in this experiment, from 12F to 26F in size.
Fig. 3. Under fluoroscopy, the ventricular septal access was dilated with a 20
French dilator, by following the super stiff back-up guide wire.ventricle, then crossed the aortic annulus, and finally
advanced into the descending aorta. Next, the soft-tip guide
wire was exchanged with a pig-tail catheter for a Lunderquist
extra stiff back-up guide wire (TSMG-35-260-LES, Cook
Medical, Limerick, Ireland). A series of dilators with
progressive diameters ranging from 12F to 26F was used to
dilate the ventricular transseptal access up to the optimal
size required for TAVI (shown in Fig. 2). At each step, the
electrocardiogram and the haemodynamic parameters were
recorded continuously, and the ventricular septum was
monitored in real time under ICE to assess the dimensions
of the ventricular septal defects (VSDs) and the shunt
between the left and right ventricles.
Finally, the 30-F sheath was positioned in ascending aorta
through the right ventricle—left ventricle (RV—LV) transsep-
tal route. The cartridge with the preloaded stent valve was
connected and transferred into the sheath as previously
described. Once the stent valve could be identified by
fluoroscopy in the ascending aorta, the sheath was slowly
pulled back, and the stent valve was released in a stepwise
fashion at the predetermined level of the aortic annulus.
2.6. Closure of both the ventricular access and the septal
access
Under the guidance of ICE and fluoroscopy, a delivery
sheath with an optimally sized muscular Amplatzer occluder
device was inserted over the Lunderquist guide wire into the
left ventricle. Then, the Amplatzer device was advanced
within its sheath, while the 30-F sheath was withdrawn, until
the left of the occluder disk was deployed on the left side of
ventricular septum (in the left ventricle). Further retraction
of the sheath over the delivery cable allowed the right disc to
be deployed on the right side of the ventricular septum (in
the right ventricle). At the end, the right ventricular access
was closed by tying the purse-string sutures prepared at the
beginning of the procedure.
2.7. Assessment of devices’ position and function
The position and function of valved stent and Amplatzer
septal occluder were assessed after their deployment for
30 min by ICE. Then, animals were sacrificed to re-examine
the position of the valved stents and the Amplatzer device at
necropsy.
Data were analysed with SPSS software (Statistical
Package for the Social Sciences). Continuous variables werereported as mean  SD. Paired Student’s t-tests was used for
comparison, where applicable, each animal being its own
control.3. Results
Procedural success of transventricular—transseptal TAVI
was 100% (5/5 animals). Mean procedure time was
49  4 min. Transventricular—transseptal access was
straightforward and there was not much difficulty to deliver
the guide wire crossing aortic annulus into the ascending
aorta under fluoroscopy. By following the guide wire, the
ventricular septal access was dilated progressively from 8F
up to 26F (Fig. 3).
Under ICE, the manipulations for dilation were monitored
and the ventricular septal access was evaluated each time.
Obvious blood shunts between the left and right ventricle
would not appear, until the septal accesses were dilated with
the 18F and over-sized dilators (Fig. 4). The size of acquired
ventricular septal defects (aVSD) was assessed at each step,
following the guide wire with ICE.
The mean diameter of native aortic annulus in pigs was
21.9  0.4 mm. All valved stents were delivered at the target
site with good acute valve function. Likewise, the Amplatzer
septal occluder devices were fully deployed and the
ventricular septal accesses were sealed successfully
(Figs. 5 and 6). All animals were in sinus rhythm before
and after the transventricular—transseptal aortic valve
implantation and device closure of the VSD. However, during
the procedure, the following electro-mechanical events
were recorded: atrial premature beat 5/5, ventricular
premature beat 4/5, sino-tachyarrhythmia 5/5, ST segment
elevation 1/5 and atrioventricular block 0/5. Likewise, the
haemodynamics were relatively stable. The heart rate was
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Fig. 4. After the ventricular septal access was dilated with 18F and oversized
dilators, an obvious blood shunt from left ventricle to the right ventricle can be
demonstrated with ICE and the colour-Doppler.
Fig. 6. Under ICE the valved stent was in aortic position with good function (A,
indicated with an arrow). The Amplatzer septal occluder device was deployed
in the accurate position, the ventricular septal access (B, the left disk of
Amplatzer closure device in the left ventricle, indicated with an arrow).90  3 beats min1 before and 100  2 beats min1 after the
procedure ( p < 0.05), whereas the arterial pressure was
assessed before (60  1 mm Hg) and after the procedure
(55  2 mm Hg: p < 0.05).
No animal had significant regurgitation or paravalvular
leak after implantation on ICE analysis. ICE demonstrated the
complete opening and closing of the implanted valves. There
were also no residual shunts detectable between the two
ventricles after deployment of Amplatzer septal occluder
device.
Macroscopic analysis of valved stents in the aortic position
confirmed the adequate positioning within the defined
landing zone, without left ventricular outflow tract obstruc-
tion and no damage to the ascending aorta or structuralFig. 5. Delivering the valved stent in the aortic annulus under the guidance of
fluoroscopy (from A to C). The valved stent and ventricular septal occluder (D)
were correctly positioned after deployment (indicated with arrows).defects of the valved stents was found at necropsy (Fig. 7).
The ventricular septal access was closed completely by the
Amplatzer septal occluder device, on gross visual examina-
tion (Fig. 7).Fig. 7. At necropsy the valved stent was in the correct position ( ), without
displacement of anterior leaflet of mitral valve and the outflow tract of left
ventricle was normal without obstruction (A, valved stent ; outflow tract of
left ventricle !). No damage to the ascending aorta or structural defects of
the valved stents was found at necropsy (B and C, valved stent ; Amplatzer
closure device !). There were obvious fingerprints of stent after the valved
stent was removed and confirmed again the valved stent was correctly
positioned in the aortic annulus (D, fingerprints of the valved stent ;
Amplatzer closure device !).
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The subxyphoid, transventricular—transseptal approach to
the aortic root appears to be a promising new route for less
invasive TAVI. Interestingly enough, onlyminor cardiac rhythm
disturbances occurred during our experiments, although the
porcine model is known for its arrhythmia and its fragile
haemodynamics. As demonstrated previously, the left side of
theheart is easilyaccessed througha subxyphoid incision in the
pig [10,11]. Such situation occurs to a less extent in the clinical
setting where mainly the diaphragmatic side of the right
ventricle is exposed from this incision. We have successfully
used the subxyphoid transventricular (RV)approach forclinical
trans-catheter pulmonary valve implantation [9]. We were
impressed by the ease of recovery and the fact that this
procedure had been realised without opening of the pleural
space and therefore it appeared that there was no need for
either intubation or pleural drainage.
The subxyphoid approach is well known to cardiac
surgeons not only for pericardial drainage [14], but also
for implantation of epicardial pacemaker leads. Some of
these procedures can also be realised with endoscopic
techniques [15,16] which have also been demonstrated for
trans-apical aortic valve implantation [6]. The most intri-
guing finding is, of course, that the subxyphoid route has also
been used in awake patients for coronary artery bypass
grafting in high risk patients [17], indeed very similar to the
patients we have for TAVI.
Hence, our interest in a transventricular—transseptal
route to the aortic root and TAVI, which may provide again a
number of interesting advantages such as:1. an extrapleural access;
2. no need for intubation;
3. no need for general anaesthesia; and
4. potential for NOTES (trans-umbilical access).
With the present study, we have been able to show, that
technically, the transventricular—transseptal approach is not
only feasible but also that the aortic root can be reached
from the right ventricle in a reliable fashion and that the
delivery of a clinical sized stent-valve can be achieved with
good functional results.
Of course, trans-apical TAVI is still an excellent and
technically mature procedure with rare local complications
and satisfying mid-term follow-up results. All of these
findings do not preclude the already established advantages
of antegrade trans-apical TAVI including superior device
performance (less compromise required for smaller intro-
ducer diameters required for peripheral access route), better
implantation control (shorter delivery systems, relatively
straight access), as well as lower risk of stroke, atrioven-
tricular block and vascular complications as compared with
peripheral retrograde routes.
Of course, there are also potential limitations for the
transventricular—transseptal approach to the aortic root.
These include the obviously necessary temporary VSD and its
potential problems including:1. to create transseptal access means increasing additional
traumatic complications to the heart;2. arrhythmias during the procedure;
3. haemodynamic consequences of a temporary VSD;
4. problems of device delivery due to suboptimal alignment;
5. feasibility of the device closure, and the reliability of the
right ventricular access closure, which might add
additional costs to the patients;6. potential risk of residual VSD, etc.
As outlined above, and very much to our surprise,
arrhythmias appeared not to be a problem in this experi-
mental set-up, and also the temporary VSD appeared to be
manageable. As a matter of fact, only the dilator sizes of 18F
and more resulted in a detectable VSD during ICE. This is in
line with the knowledge compiled from atrial transseptal
procedures, where small atrial septal defects (ASDs) created
for diagnostic and/or therapeutic purposes do usually not
require closure devices [18]. In addition, we allowed here for
a stabilisation period to assess the sizes/consequences of the
VSDs between the dilators of increasing size, whereas for the
clinical setting, we would certainly replace immediately
each dilator with the next one and therefore allow between
the steps only for minimal time period of shunting due to the
VSD. Furthermore, one can expect some degree of septal
hypertrophy in clinical cases with severe aortic stenosis,
which, in turn, will induce a longer intraseptal route and
therefore reduce the potential for shunting, correspondingly.
With regard to suboptimal device alignment due to the
eccentric initial puncture, we did not, in fact, encounter any
problem with device delivery, which was always smooth.
Likewise, antegrade exploration of the aortic root with a soft
J-type guide wire at the beginning of the procedure was
straightforward. It may be of interest to revise the perceived
impression, that the trans-apical route to the aortic root is
perfectly straight. As a matter of fact, a quite significant
angulation can occur as shown in Fig. 8, where the apical
access spot and the aortic annulus look perfectly aligned in
the antero-posterior projection, but the lateral view
provides a very different reality. As a matter of fact, there
is an angle of at least 608 in this patient with excellent
outcome. Hence, a moderate angle of 308 or less, which is
typically seen with the transventricular—transseptal route,
appears not to be a problem and is of course much less than
what is observed with the peripheral access routes where
several curves occur, which may exceed 1808.
Therefore, transventricular—transseptal TAVI via a sub-
xyphoidian access might have the following unique advan-
tages: There is no manipulation within pleural space. Therefore,
one can expect less interference with the respiratory
system. This is especially suitable for patients with
concomitant respiratory diseases and poor pulmonary
function, or those who have received prior operations
within the left thoracic cavity or on the left ventricle (such
as, left ventricular aneurysmectomy), with severe pleural
adhesions or pericardial adhesions, which can make
exposure of the apex of the heart more difficult. It provides a possibility of TAVI under epidural and/or local
anaesthesia without the requirement of intubation, which
will further minimise invasiveness and benefit patients’
rehabilitation.
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Fig. 8. Although an anterior-posterior chest view suggest an almost perfect
alignment between the apical access and the aortic annulus, this is not
necessarily true. As a matter of fact, the left lateral radiograph after
trans-apical aortic valved stent implantation shows that the direction of
trans-apical procedure is not parallel to the axis of aortic annulus and there
is an obvious angle between them. By using the principle of NOTES in combination with the
transventricular—transseptal access, an access route via
the umbilicus is more feasible, provided closure tight
devices become available. Easier to control bleeding from right ventricular access.
The transventricular—transseptal access is on the right
side of the heart with lower blood pressure, compared withthe left ventricle, which, in turn, makes closure easier not
only with sutures, but also by themeans of closure devices.
In this experiment, no difficulties were encountered during
closure of right ventricular access.
In short, transventricular—transseptal access for TAVI is a
novel experimental exploration, which might enrich the
routes for trans-catheter aortic valved stent implantation.
Theoretically, it might be applied to those patients without
indications for ‘traditional’ approaches (such as, transfe-
moral or trans-apical) TAVI. Considering the anatomic
differences between human heart (patient’s diseased heart)
and swine heart, further researches will be carried out before
its possible clinical application.Acknowledgement
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With the event of trans-catheter aortic-valve implanta-
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developing devices to facilitate trans-apical aortic-valve
implantation, this approach seems a little bit circumstan-
tial. It is argued that opening the pleura can be avoided
using a subxyphoidal approach and that general anesthesia
may therefore no longer be needed. The requirement of
general anesthesia for trans-apical aortic-valve implanta-
tion is continuously brought forward as a disadvantage
when compared with the transfemoral access, which is now
more often performed in local anesthesia. However, it has
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aortic-valve implantation through the 5th or 6th left
intercostal space can also be performed in the awake,
spontaneously breathing patient using high epidural
analgesia and despite pleural opening. However, there
are other good reasons to favor general anesthesia in the
setting of trans-catheter valve implantation. First, severe
and life-threatening complications requiring cardiopul-
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Second, uncontrolled motion of the patient during valve
deployment can unarguably lead to valve dislocation, a
problem that can easily be avoided if the patient is asleep.
Not general anesthesia itself, but prolonged ventilation is
disadvantageous for the patient. Trans-catheter valve
implantation should therefore go in hand with a fast-track
anesthesia concept, applying short-acting anesthetics and
early extubation.
The creation of an iatrogenic ventricular septal defect
(VSD) is required for the proposed access. While this was
successfully treated with the application of an Amplatzer
occluder, the reasonableness of means can be put to
question. Percutaneous closure of a VSD is associated with
a relatively high risk of both peri-interventional and
potential long-term complications. These include, but are
not limited to, incomplete closure with residual shunt, the
risk of device embolisation and migration, thrombo-
embolic complications (pulmonary and systemic), hemo-
lysis, arrhythmias and the risks associated with the need
for anticoagulation are added to the procedure. Trans-
catheter valve implantation is already expensive; the
addition of devices to treat access-related collateral
damage would further increase the economic burden.
For cases in whom standard aortic-valve replacement is
truly not an option and neither the transfemoral, transsub-
clavian nor the trans-apical approach is feasible, a direct
trans-aortic approach may be useful [5]. We must also accept
that, even in 2010, some patients may be served best with no
intervention at all.
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